Cargando…

IDH-Mutated AML: Beyond Enasidenib and Ivosidenib Monotherapy: Highlights From SOHO 2021

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Harborside Press LLC 2022
Materias:	Meeting Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8824283/ https://www.ncbi.nlm.nih.gov/pubmed/35186402 http://dx.doi.org/10.6004/jadpro.2022.13.1.11

Ejemplares similares

Beyond Hyper-CVAD in ALL: Highlights From SOHO 2021
Publicado: (2022)

Therapeutic Updates for Richter Syndrome: Highlights From SOHO 2021
Publicado: (2022)

Updates on Clinical Trials for Myelofibrosis: Highlights From SOHO 2021
Publicado: (2022)

Immunotherapy Approaches in T-Cell Lymphoma: Highlights From SOHO 2021
Publicado: (2022)

Targeting p53 in MDS: Highlights From SOHO 2021
Publicado: (2022)

BCMA-Directed CAR T Cells in Relapsed Refractory Multiple Myeloma: Highlights From SOHO 2021
Publicado: (2022)

Novel Treatment Approaches in Relapsed/Refractory Mantle Cell Lymphoma: Highlights From SOHO 2021
Publicado: (2022)

The Next Wave of Novel Agents in Aggressive B-Cell Lymphoma: Highlights From SOHO 2021
Publicado: (2022)

New CAR Designs: Highlights From SOHO 2020
Publicado: (2021)

Emerging Therapies in Myelofibrosis: Highlights From SOHO 2020
Publicado: (2021)

Immunotherapy for T-Cell ALL and T-NHL: Highlights From SOHO 2020
Publicado: (2021)

Oral Hypomethylating Agents for Myelodysplastic Syndromes: Highlights From SOHO 2020
Publicado: (2021)

Minimal Residual Disease in Chronic Lymphocytic Leukemia: Highlights From SOHO 2020
Publicado: (2021)

Managing Relapsed Disease in Peripheral T-Cell Lymphoma: Highlights From SOHO 2020
Publicado: (2021)

Predicting Drug Response in Acute Lymphoblastic Leukemia: Highlights From SOHO 2020
Publicado: (2021)

Pharmacokinetic/Pharmacodynamic Evaluation of Ivosidenib or Enasidenib Combined With Intensive Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed IDH1/2‐Mutant Acute Myeloid Leukemia
por: Fan, Bin, et al.
Publicado: (2022)

Integrating Novel Agents in Relapsed or Refractory Hodgkin Lymphoma: Highlights From SOHO 2020
Publicado: (2021)

Updates on Therapeutic Advancements in Relapsed or Refractory Multiple Myeloma: Highlights From SOHO 2020
Publicado: (2021)

Secondary IDH1 resistance mutations and oncogenic IDH2 mutations cause acquired resistance to ivosidenib in cholangiocarcinoma
por: Cleary, James M., et al.
Publicado: (2022)

Ivosidenib for IDH1 Mutant Cholangiocarcinoma: A Narrative Review
por: Sumbly, Vikram, et al.
Publicado: (2022)

Ivosidenib: IDH1 Inhibitor for the Treatment of Acute Myeloid Leukemia
por: Merchant, Shelby L., et al.
Publicado: (2019)

Enasidenib: An Oral IDH2 Inhibitor for the Treatment of Acute Myeloid Leukemia
por: Myers, Rebecca A., et al.
Publicado: (2018)

Enasidenib as maintenance following allogeneic hematopoietic cell transplantation for IDH2-mutated myeloid malignancies
por: Fathi, Amir T., et al.
Publicado: (2022)

The IDH1 inhibitor ivosidenib improved seizures in a patient with drug-resistant epilepsy from IDH1 mutant oligodendroglioma
por: Vo, Anh Huan, et al.
Publicado: (2022)

The Advanced Practitioner's Role in Treating Patients With Hematologic Malignancies: Highlights From SOHO 2021
por: Geppner, Alexis C.
Publicado: (2022)

Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome
por: DiNardo, Courtney D., et al.
Publicado: (2022)

Case report of combination therapy with Azacytidine, Enasidenib and Venetoclax in primary refractory AML
por: Jasra, Sakshi, et al.
Publicado: (2021)

Clinical Utility of Ivosidenib in the Treatment of IDH1-Mutant Cholangiocarcinoma: Evidence To Date
por: Uson Junior, Pedro Luiz Serrano, et al.
Publicado: (2023)

Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial
por: de Botton, Stéphane, et al.
Publicado: (2023)

Ivosidenib, an IDH1 inhibitor, in a patient with recurrent, IDH1-mutant glioblastoma: a case report from a Phase I study
por: Tejera, Dalissa, et al.
Publicado: (2020)

Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy
por: Venugopal, Sangeetha, et al.
Publicado: (2022)

Evaluating ivosidenib for the treatment of relapsed/refractory AML: design, development, and place in therapy
por: Nassereddine, Samah, et al.
Publicado: (2018)

P441: CLINICAL AND MOLECULAR CHARACTERISTICS OF AML PATIENTS WITH AN EXCEPTIONAL RESPONSE TO IVOSIDENIB
por: Watts, Justin M., et al.
Publicado: (2023)

Ivosidenib in Isocitrate Dehydrogenase 1–Mutated Advanced Glioma
por: Mellinghoff, Ingo K., et al.
Publicado: (2020)

Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers
por: Popovici-Muller, Janeta, et al.
Publicado: (2018)

Ivosidenib: First Global Approval
por: Dhillon, Sohita
Publicado: (2018)

Updated survival outcomes with ivosidenib in patients with previously treated IDH1-mutated intrahepatic-cholangiocarcinoma: an Italian real-world experience
por: Rimini, Margherita, et al.
Publicado: (2023)

Population pharmacokinetic and exposure‐response analyses of ivosidenib in patients with IDH1‐mutant advanced hematologic malignancies
por: Jiang, Xuemin, et al.
Publicado: (2021)

P724: UPDATED SUBSTUDY RESULTS FOR IVOSIDENIB IN IDH1-MUTANT RELAPSED/REFRACTORY MYELODYSPLASTIC SYNDROME
por: Dinardo, Courtney, et al.
Publicado: (2023)

Efficacy and Safety Profile of Ivosidenib in the Management of Patients with Acute Myeloid Leukemia (AML): An Update on the Emerging Evidence
por: Stemer, Galia, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_cetdqp9euh79mi87i5ui1nuk48